August 30, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator and market leader, announces the appointment of Marvin Washington, VP of business development for Isodiol International Inc. and brand ambassador for ISO-Sport, to its Board of Directors. Mr. Washington is a retired NFL player who played a total of eleven years with three teams: the New York Jets, Denver Broncos and San Francisco 49ers and also won a Superbowl title.
A voice for former NFL players in the NFL’s concussion lawsuit, Mr. Washington addresses the truth about the outcome as well as the effects of chronic traumatic encephalopathy (CTE). An advocate for all-natural, non-habit forming cannabis, Washington is speaking out on the topic of using cannabinoids as neuroprotectants as well as an avenue to alleviate the nation’s #1 health epidemic: prescription opioid abuse and addiction.
Mr. Washington is a graduate of Idaho University and a 2004 inductee into the University of Idaho Vandal Sports Hall of Fame. After football Mr. Washington worked for William Small Wealth Management Group as a Financial Advisor. Mr. Washington worked in financial services for 10 years focusing on financial planning, retirement planning and estate planning.
Now a serial entrepreneur, Mr. Washington is focused on the cannabis industry. He is an investor and co-owner of a number of cannabis ventures. Mr. Washington is also a NFL league ambassador for Athletes For Care and is a member of the Board of Directors. Mr. Washington has been instrumental in starting discussion with the NFL Players Association for changes in the sport’s drug policies.
“With the appointment of Marvin Washington to the Board of Directors, Isodiol continues to add excellent leadership to its team,” said CEO of Isodiol, Marcos Agramont. “Mr. Washington is a very well known public figure that has made headways with the National Football League on CTE and how CBD can be a great alternative to opioids and pharmaceuticals that many players take today. With Mr. Washington on board, the Company will continue to spread the message of CBD and its health benefits for the human body.”
The Company also announces Bryan Loree has stepped down from the Board of Directors of Isodiol. The Company wishes to thank Mr. Loree for his hard work and services to the Company.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.